Codexis, Inc.
NASDAQ:CDXSBiotechnology
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
Volume 1.47M
Average 1.15M
CDXS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Codexis, Inc.NASDAQ: CDXS
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $3.31M rose 21.2% year over year, ahead of the -11.5% change in trailing-twelve-month cost of revenue. Sequentially, it fell 1.5% from the prior quarter. Over 3 fiscal years it compounded at -37.4% a year.
Context
- Cost of revenue amounted to 13.3% of revenue in FY2025, down 14.2 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +21.2% holds above the trailing-twelve-month pace of -11.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 9.34M USD
- Year-over-year change
- -42.7%
- 4-year CAGR
- -19.5%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.34M | -42.7% |
| FY2024 | 2024-12-31 | 16.29M | +27.2% |
| FY2023 | 2023-12-31 | 12.81M | -66.3% |
| FY2022 | 2022-12-31 | 38.03M | +71.3% |
| FY2021 | 2021-12-31 | 22.21M | — |
Cost of Revenue vs competitors
How CDXS compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.5% is the 2nd highest of 6, against a peer median of -40.6%.
- Cost of revenue amounts to 16.1% of revenue for CDXS, versus a peer median of 6.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $18.66M USD | — | — | 64.5% | |
| LTM Mar 2026 | $12.54M USD | -11.5% | -37.4% | 16.1% | |
| LTM Mar 2026 | $4.46M USD | +81.8% | — | 8.0% | |
| LTM Mar 2026 | $1.8M USD | -69.3% | — | 5.2% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $1.57M USD | -13.9% | +58.2% | 80.5% |
| LTM Mar 2026 | $823K USD | -40.6% | -64.8% | 27.8% | |
| LTM Mar 2026 | $161K USD | — | — | 5.1% | |
| LTM Mar 2026 | $90K USD | — | — | — | |
| FY2025 | €0 EUR | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | -14.4% | 0.0% | |
| Peer median (excluding CDXS) | — | -40.6% | -14.4% | 6.6% | |
Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 104.75M | 138.59M | 70.14M | 59.35M | 70.39M |
| Cost of Revenue | 22.21M | 38.03M | 12.81M | 16.29M | 9.34M |
| Gross Profit | 82.55M | 100.56M | 57.33M | 43.06M | 61.05M |
| Gross Margin | 78.8% | 72.6% | 81.7% | 72.6% | 86.7% |
| Research & Development | 55.92M | 80.1M | 58.89M | 46.26M | 52.31M |
| Selling, General & Admin | 49.32M | 52.17M | 53.25M | 55.15M | 47.07M |
| Operating Expenses | 105.24M | 135.44M | 125.4M | 101.58M | 99.38M |
| Depreciation & Amortization | 5.95M | 5.4M | 5.52M | 4.95M | 5.25M |
| EBITDA | (15.14M) | (26.31M) | (49.28M) | (53.41M) | (33.87M) |
| EBITDA Margin | -14.5% | -19.0% | -70.3% | -90.0% | -48.1% |
| Operating Income | (22.7M) | (34.88M) | (68.07M) | (58.52M) | (38.33M) |
| Operating Margin | -21.7% | -25.2% | -97.0% | -98.6% | -54.5% |
| Interest Income | 459K | 1.44M | 4.17M | 3.67M | 2.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 4.81M |
| Other Income / Expenses | 1.61M | 1.57M | (8.1M) | (6.72M) | (5.6M) |
| Income Before Tax | (21.09M) | (33.32M) | (76.17M) | (65.24M) | (43.93M) |
| Pre-Tax Margin | -20.1% | -24.0% | -108.6% | -109.9% | -62.4% |
| Income Tax Expense | 189K | 276K | 69K | 34K | 47K |
| Net Income | (21.28M) | (33.59M) | (76.24M) | (65.28M) | (43.97M) |
| Net Margin | -20.3% | -24.2% | -108.7% | -110.0% | -62.5% |
| EPS (Basic) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| EPS (Diluted) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| Weighted Avg Shares | 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
| Weighted Avg Shares (Diluted) | 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
Codexis, Inc.
NASDAQ:CDXS
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.